|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's Range||80.75 - 82.48|
|52 Week Range||74.31 - 129.59|
|Beta (3Y Monthly)||0.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 29, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||119.10|
NEW YORK, Aug. 19, 2019 -- iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered into a Master Services Agreement (“MSA”) with Lung Biotechnology PBC, a.
Martine Rothblatt became the CEO of United Therapeutics Corporation (NASDAQ:UTHR) in 2016. First, this article will...
Zoetis (ZTS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , Aug. 6, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt , Ph.D., Chairman and Chief Executive ...
United Therapeutics (UTHR) beats estimates on both fronts in the second quarter. Loss of exclusivity for Adcirca and lower sales of Remodulin hurts sales.
Martine Rothblatt is advancing her plan to triple United Therapeutics Corp.’s business over the next few years.
United Therapeutics (UTHR) delivered earnings and revenue surprises of 51.25% and 12.60%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 31, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the quarter ended June 30, 2019. ...
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , July 24, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2019 financial ...
While small-cap stocks, such as United Therapeutics Corporation (NASDAQ:UTHR) with its market cap of US$3.3b, are...
The judge’s decision came after more than an hour and a half of discussion in a cavernous courtroom.
The recent weakness in United Therapeutics stock is attributable to concerns over generic competition for its pulmonary arterial hypertension drug Remodulin and shareholder base churn, Auster said in the Monday upgrade note.
Shares of the biotech firm United Therapeutics rose after Credit Suisse said the recent cratering of the stock’s price was undeserved.
Arena (ARNA) doses first patient in one of the two pivotal late-stage studies evaluating its pipeline candidate, etrasimod in ulcerative colitis indication.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
The merger comes while a subsidiary is expanding in Jacksonville and possibly pursuing city incentives.
United Therapeutics Corp NASDAQ/NGS:UTHRView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for UTHR with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting UTHR. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding UTHR totaled $388 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.